Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.hrthm.2021.12.034 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Bimekizumab-bkzx for the Treatment of Plaque Psoriasis: A Drug Review.
Ann Pharmacother
October 2024
Center for Dermatology Research, Department of Dermatology, School of Medicine, Wake Forest University, Winston-Salem, NC, USA.
Background: Bimekizumab is a biologic targeting interleukin (IL)-17A/17F, approved by the Food and Drug Administration (FDA) for moderate-to-severe plaque psoriasis in 2023.
Data Sources: A PubMed search was performed using the keywords "bimekizumab," "plaque psoriasis," and "bimekizumab clinical trials," from origin to August 1, 2024. We included phase I to III trials of bimekizumab for plaque psoriasis, studies published post-FDA approval, and information from the package insert.
Broad immunogenicity to prior SARS-CoV-2 strains and JN.1 variant elicited by XBB.1.5 vaccination in nursing home residents.
Geroscience
October 2024
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Article Synopsis
- SARS-CoV-2 vaccinations have decreased hospitalization and death rates in nursing home residents, but effectiveness is challenged by new variants and reduced immunity.
- A study evaluated the immune response to the XBB.1.5 monovalent vaccine in nursing home residents and healthcare workers, focusing on those with prior infections.
- Results showed a significant increase in neutralizing antibody levels, especially in nursing home residents who had a previous infection, indicating the vaccine's ability to enhance immunity against Omicron variants.
Clinical Benefits of DaxibotulinumtoxinA for Injection: Beyond Glabellar Line Effacement?
Dermatol Surg
September 2024
Revance Therapeutics, Inc., Nashville, Tennessee.
Background: Botulinum toxin type A (BoNTA) is standard of care for glabellar lines ameliorization. DaxibotulinumtoxinA for Injection (DAXI) is a new BoNTA with a unique formulation representing the latest advancement in BoNTA technology. There is an unmet need for patients to understand the full potential of BoNTA treatment and new technologies.
View Article and Find Full Text PDFRenal Denervation for Hypertension: The Current Landscape and Future Directions.
Heart Int
April 2024
Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Hypertension (HTN) is one of the largest contributors to cardiovascular (CV) morbidity and mortality in the USA and is estimated to affect 47% of the US population; however, recent estimates suggest that over 40% continue to have uncontrolled HTN. In the past decade, multiple placebo-controlled randomized studies have shown the safety and efficacy of renal denervation as an adjunctive therapy, culminating in the recent approval of two devices by the US Food and Drug Administration (FDA). These devices use either radiofrequency or ultrasound energies to ablate the perivascular sympathetic nerves in the renal arteries and have been shown to reduce blood pressure.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!